Size: | Price | Quantity | |
---|---|---|---|
5 mg | $50.00 | ||
25 mg | $150.00 |
C19-9 (1477482-47-5) is a novel non-RGD inhibitor of the integrin αvß3 receptor (KD = 102 nM). It was active against the human prostate carcinoma epithelial cell line 22RV1 (IC50 = 467 nM) and human prostate cancer organoids (IC50 = 652 nM). C19-9 was active in vivo in 22RV1 mouse xenografts and blocked growth in enzalutamide-resistant mouse CRPC xenografts.
References/Citations:
C16H18N4O3
>98% by TLC
NMR: (Conforms)
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
C19-9 (1477482-47-5) is a novel non-RGD inhibitor of the integrin αvß3 receptor (KD = 102 nM). It was active against the human prostate carcinoma epithelial cell line 22RV1 (IC50 = 467 nM) and human prostate cancer organoids (IC50 = 652 nM). C19-9 was active in vivo in 22RV1 mouse xenografts and blocked growth in enzalutamide-resistant mouse CRPC xenografts.
References/Citations:
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.